Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers
Gynecological cancers including breast, cervical, ovarian, uterine, and vaginal, pose the
greatest threat to world health, with early identification being crucial to patient outcomes and …
greatest threat to world health, with early identification being crucial to patient outcomes and …
Implications of Toll-like receptors (TLRs) and their signaling mechanisms in human cancers
SA Chandrasekar, T Palaniyandi… - … -Research and Practice, 2023 - Elsevier
Most essential pattern-recognition receptors regulating innate immune functions are toll-like
receptors (TLRs). TLRs are characterized by lack of concurrent epithelial markers and are …
receptors (TLRs). TLRs are characterized by lack of concurrent epithelial markers and are …
A systematic review of family history, race/ethnicity, and genetic risk on prostate cancer detection and outcomes: considerations in PSA-based screening
NJ Graham, LH Souter, SS Salami - Urologic Oncology: Seminars and …, 2024 - Elsevier
Aim To investigate the role of family history, race/ethnicity, and genetics in prostate cancer
(PCa) screening. Methods We conducted a systematic review of articles from January 2013 …
(PCa) screening. Methods We conducted a systematic review of articles from January 2013 …
LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy
Paclitaxel (PTX) is widely used for treating several cancers, including breast, ovarian, lung,
esophageal, gastric, pancreatic, and neck cancers. Despite its clinical utility, cancer …
esophageal, gastric, pancreatic, and neck cancers. Despite its clinical utility, cancer …
The risk factors and screening uptake for prostate Cancer: a sco** review
Objectives: The purpose of this sco** review was to identify the risk factors and screening
uptake for prostate cancer. Design: Sco** review. Methods: Arksey and O'Malley's …
uptake for prostate cancer. Design: Sco** review. Methods: Arksey and O'Malley's …
Oncogenic role of FOXM1 in human prostate cancer
DY Lee, JN Chun, I So, JH Jeon - Oncology Reports, 2023 - spandidos-publications.com
Prostate cancer is the leading cause of cancer-related mortality among men worldwide. In
particular, castration-resistant prostate cancer presents a formidable clinical challenge and …
particular, castration-resistant prostate cancer presents a formidable clinical challenge and …
[HTML][HTML] Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy
RJ Salloom, IM Ahmad, DZ Sahtout, MJ Baine… - International Journal of …, 2024 - mdpi.com
Prostate cancer (PC) is a significant cause of mortality in men worldwide, hence the need for
a comprehensive understanding of the molecular mechanisms underlying its progression …
a comprehensive understanding of the molecular mechanisms underlying its progression …
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression
T Redmer, M Raigel, C Sternberg, R Ziegler, C Probst… - Molecular Cancer, 2024 - Springer
Background Prostate cancer develops through malignant transformation of the prostate
epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription …
epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription …
Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer
Y Liu, A Chen, Y Wu, J Ni, R Wang, Y Mao, N Sun… - Cell Death & …, 2025 - nature.com
We here investigate the expression of the mitochondrial carrier homolog 2 (MTCH2) and its
potential function in castration-resistant prostate cancer (CRPC). Bioinformatic analyses …
potential function in castration-resistant prostate cancer (CRPC). Bioinformatic analyses …
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes
E Ribeiro, B Costa, L Marques… - Journal of Clinical …, 2024 - pmc.ncbi.nlm.nih.gov
Backgroud: This study investigates the potential of vasodilator drugs as additive therapy in
the treatment of urological cancers, particularly in combination with the antineoplastic agent …
the treatment of urological cancers, particularly in combination with the antineoplastic agent …